| Literature DB >> 12450567 |
Ryan R Metzger1, Jeffrey M Brown, Verónica Sandoval, Kristi S Rau, Mohamed A Elwan, Gary W Miller, Glen R Hanson, Annette E Fleckenstein.
Abstract
Previous studies indicate that reserpine may disrupt dopamine transporter activity. Results presented herein reveal that it also inhibits potently synaptosomal [3H]dopamine uptake. In addition, reserpine administration to rats decreased the V(max) of synaptosomal dopamine transport, as assessed ex vivo 12 h after treatment. This decrease appeared, at least in part, dissociated from concurrent inhibition of the vesicular monoamine transporter-2 (VMAT-2). In separate experiments, synaptosomal dopamine uptake did not differ between wild-type and heterozygous VMAT-2 knockout mice, and reserpine treatment did not inhibit [3H]dopamine uptake into cells heterogously expressing the human dopamine transporter. Taken together, these data suggest that reserpine may transiently alter dopamine transporter function in a noncompetitive, indirect manner.Entities:
Mesh:
Substances:
Year: 2002 PMID: 12450567 DOI: 10.1016/s0014-2999(02)02647-x
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432